Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;32(3):245-9.
doi: 10.1016/j.mri.2013.10.013. Epub 2013 Dec 14.

Assessing reproducibility of diffusion-weighted magnetic resonance imaging studies in a murine model of HER2+ breast cancer

Affiliations

Assessing reproducibility of diffusion-weighted magnetic resonance imaging studies in a murine model of HER2+ breast cancer

Jennifer G Whisenant et al. Magn Reson Imaging. 2014 Apr.

Abstract

Background and purpose: The use of diffusion-weighted magnetic resonance imaging (DW-MRI) as a surrogate biomarker of response in preclinical studies is increasing. However, before a biomarker can be reliably employed to assess treatment response, the reproducibility of the technique must be established. There is a paucity of literature that quantifies the reproducibility of DW-MRI in preclinical studies; thus, the purpose of this study was to investigate DW-MRI reproducibility in a murine model of HER2+ breast cancer.

Materials and methods: Test-Retest DW-MRI scans separated by approximately six hours were acquired from eleven athymic female mice with HER2+ xenografts using a pulsed gradient spin echo diffusion-weighted sequence with three b values [150, 500, and 800s/mm(2)]. Reproducibility was assessed for the mean apparent diffusion coefficient (ADC) from tumor and muscle tissue regions.

Results: The threshold to reflect a change in tumor physiology in a cohort of mice is defined by the 95% confidence interval (CI), which was±0.0972×10(-3)mm(2)/s (±11.8%) for mean tumor ADC. The repeatability coefficient defines this threshold for an individual mouse, which was±0.273×10(-3)mm(2)/s. The 95% CI and repeatability coefficient for mean ADC of muscle tissue were±0.0949×10(-3)mm(2)/s (±8.30%) and±0.266×10(-3)mm(2)/s, respectively.

Conclusions: Mean ADC of tumors is reproducible and appropriate for detecting treatment-induced changes on both an individual and mouse cohort basis.

Keywords: Apparent diffusion coefficient; Diffusion-weighted MRI; Mouse; Reproducibility.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: T.E.Y. is a consultant for Eli Lilly and Company. No other authors declare any conflicts of interest.

Figures

Fig. 1
Fig. 1
Test–retest example of ADC parametric maps. Three regions of interest are indicated: tumor (denoted with a ‘T’), skeletal muscle (denoted with ‘M’), and a water phantom (denoted with a ‘W’). Take note of how the animal orientation is slightly different between repeat scans, which might affect ADC reproducibility as the same tissue sections from each scan might not be analyzed. This variation in positioning is somewhat noticeable in the tumor, as the location and size of higher ADC regions (white arrows) are different; however, the variability of regions with higher ADC values (red arrows) is much larger in the muscle. Units of ADC are in mm2/s.
Fig. 2
Fig. 2
Bland–Altman plots displaying the difference in ADC between scans plotted against mean ADC for both tumor (left panel) and muscle (right panel) ROIs. The mean difference (solid line) is shown with 95% confidence intervals (dotted lines), which defines the significant threshold for the population. Repeatability is also shown (dashed lines), and represents the threshold required to guarantee a statistically significant change in an individual mouse.

Similar articles

Cited by

References

    1. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–150S. - PMC - PubMed
    1. Guarneri V, Barbieri E, Dieci MV, Piacentini F, Conte P. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treat Rev. 2010;36(Suppl 3):S62–S66. - PubMed
    1. Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer. 2007;7(2):107–117. - PubMed
    1. Galons JP, Altbach MI, Paine-Murrieta GD, Taylor CW, Gillies RJ. Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia. 1999;1(2):113–117. - PMC - PubMed
    1. Jensen LR, Garzon B, Heldahl MG, Bathen TF, Lundgren S, Gribbestad IS. Diffusion-weighted and dynamic contrast-enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients. J Magn Reson Imaging. 2011;34(5):1099–1109. - PubMed

Publication types